{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:17:34Z","timestamp":1781569054599,"version":"3.54.5"},"reference-count":55,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPR"],"DOI":"10.2147\/jpr.s270169","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T04:27:58Z","timestamp":1600748878000},"page":"2343-2354","source":"Crossref","is-referenced-by-count":28,"title":["<p>Characteristics of Analgesic Patch Formulations<\/p>"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Srinivas","family":"Nalamachu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0304-3959(95)00146-8","volume":"65","author":"Rowbotham","year":"1996","journal-title":"Pain"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","volume":"18","author":"Simpson","year":"2017","journal-title":"The Journal of Pain"},{"key":"ref3","unstructured":"Endo Pharmaceuticals Inc. Lidoderm (Lidocaine Patch 5%) Prescribing Information. MalvernPA: Endo Pharmaceuticals Inc; 2015."},{"key":"ref4","unstructured":"Scilex Pharmaceuticals Inc. ZTLIDO (Lidocaine Topical System) Prescribing Information. San Diego, CA: Scilex Pharmaceuticals Inc; 2018."},{"key":"ref5","unstructured":"Pfizer Inc. Flector (Diclofenac Epolamine Topical System) Prescribing Information. Pfizer Inc: New York, NY; 2019."},{"key":"ref6","unstructured":"Galen US Inc. Synera \u00ae(Lidocaine and Tetracaine) Topical Patch Prescribing Information. Souderton, PA: Galen US Inc; 2018."},{"key":"ref7","unstructured":"NeurogesX, Inc. Qutenza \u00ae (Capsaicin 8% Patch) Prescribing Information. San Mateo, CA:NeurogesX, Inc."},{"key":"ref8","unstructured":"Janssen Pharmaceuticals, Inc. Duragesic (Fentanyl Transdermal System) Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2018."},{"key":"ref9","unstructured":"Purdue Pharma L.P. Butrans \u00ae (Buprenorphine Transdermal System) Prescribing Information. Stamford, CT: Purdue Pharma L.P; 2014."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1600-0846.2008.00316.x","volume":"14","author":"Tanner","year":"2008","journal-title":"Skin Res and Tech"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.22159\/ajpcr.2016.v9i6.13775","volume":"9","author":"Mathews","year":"2016","journal-title":"Asian J Pharmaceutical Clin Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/bph.13059","volume":"172","author":"Pastore","year":"2015","journal-title":"Br J Pharmacol"},{"key":"ref13","first-page":"15","volume":"44","author":"Lisi","year":"2019","journal-title":"US Pharm"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2146\/ajhp110158","volume":"69","author":"Durand","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"ref15","first-page":"129","volume":"3","author":"Hughes","year":"2013","journal-title":"J Nurs Edu Pract"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2006.03.009","volume":"64","author":"Wokovich","year":"2006","journal-title":"Eur J Pharmaceutics Biopharmaceutic"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/bjaceaccp\/mkq054","volume":"11","author":"Bajaj","year":"2011","journal-title":"Continu Educ Anaesthesia Critical Care Pain"},{"key":"ref18","unstructured":"Fentanyl Transdermal System. Prescribing Information. Bedminster, NJ: Mallinckrodt Pharmaceuticals; 2018."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1310\/hpj4510-771","volume":"45","author":"Hong","year":"2010","journal-title":"Hosp Pharm"},{"key":"ref20","unstructured":"Wilbur RL The Difference Between Topical and Transdermal Medications. 2017 Genesco Pharma. Miami, FL. Available from: https:\/\/genscopharma.com\/difference-topical-transdermal-medications\/. Accessed April 2, 2020."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1523-1747.2003.12359.x","volume":"121","author":"Madison","year":"2003","journal-title":"J Invest Dermatol"},{"key":"ref22","first-page":"1001","volume":"8","author":"Roy","year":"2017","journal-title":"Int J Pharmaceutical Sci and Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/J426v02n04_02","volume":"2","author":"Nalamachu","year":"2006","journal-title":"J Neuropathic Pain Symptom Palliation"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1517\/17425247.2012.637107","volume":"9","author":"Cilurzo","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"ref25","unstructured":"European Medicines Agency Guidelines on quality of transdermal patches 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-transdermal-patches_en.pdf. Accessed: April 2, 2020."},{"key":"ref26","unstructured":"US Food and Drug Administration. Assessing adhesion with transdermal and topical delivery systems for ANDAs \u2013 guidance for Industry (Draft Guidance); 2018. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-adhesion-transdermal-delivery-systems-and-topical-patches-andas-draft-guidance-industry. Accessed May 1, 2020."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/00325481.2019.1702296","volume":"132","author":"Gudin","year":"2020","journal-title":"Postgrad Med"},{"key":"ref28","unstructured":"US Food and Drug Administration. Guidance for Industry Residual Drug in Transdermal and Related Drug Delivery Systems; 2011. Available from: www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm. Accessed Jan 5, 2020."},{"key":"ref29","unstructured":"US Food and Drug Administration. Fentanyl Patch Can Be Deadly to children; 2012. Available from: https:\/\/www.fda.gov\/consumers\/consumer-updates\/fentanyl-patch-can-be-deadly-children. Accessed Jan. 5, 2020."},{"key":"ref30","unstructured":"Mylan Pharmaceuticals Inc. Lidocaine (Lidocaine Patch) Prescribing Information. Morgantown, WV: Mylan Pharmaceuticals Inc; 2018."},{"key":"ref31","unstructured":"US Food and Drug Administration. Abbreviated New Drug Application (ANDA). 2019 Available from: https:\/\/www.fda.gov\/drugs\/types-applications\/abbreviated-new-drug-application-anda. Accessed May 1, 2020."},{"key":"ref32","volume-title":"Adhesion Performance of 3 Lidocaine Patch Formulations","year":"2018"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1113\/jphysiol.2007.134262","volume":"582:","author":"Sheets","year":"2007","journal-title":"J Physiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1185\/03007995.2012.690339","volume":"28","author":"Mick","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0304-3959(98)00244-9","volume":"80","author":"Galer","year":"1999","journal-title":"Pain"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ana.410370216","volume":"37","author":"Rowbotham","year":"1995","journal-title":"Ann Neurol"},{"key":"ref37","unstructured":"US Food and Drug Administration. FDA Adverse Events Reporting System (FAERS) Public Dashboard. 2018. Available at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed July 27, 2018."},{"key":"ref38","unstructured":"US Food and Drug Administration. FDA Adverse Events Reporting System 9FAERS Public Dashboard; 2018. Available from: https:\/\/www.fda.gov\/drugs\/fda-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files. Accessed February 13, 2020."},{"key":"ref39","unstructured":"Drugs.com User Reviews for Lidoderm. Available from: https:\/\/www.drugs.com\/comments\/lidocaine-topical\/lidoderm.html. Accessed September 12, 2019."},{"key":"ref40","unstructured":"Drugs.com User Reviews for Topical Lidocaine. Available from: https:\/\/www.drugs.com\/comments\/lidocaine-topical\/. Accessed Nov.17, 2019."},{"key":"ref41","unstructured":"PissedConsumer.com Mylan Lidocaine Transdermal Patch Reviews and Complaints. Available from:: https:\/\/mylan.pissedconsumer.com\/mylan-lidocaine-transdermal-patch-4455\/complaints\/RT-CP.html. Accessed Nov 18, 2019."},{"key":"ref42","unstructured":"EMLA Cream, EMLA Patch. Product Monograph. Toronto, Ontario: Aspen Pharmacare Canada, Inc; 2017."},{"key":"ref43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1756285613496862","volume":"6","author":"Baranidharan","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/bja\/aer260","volume":"107","author":"Anand","year":"2011","journal-title":"Br J Anaesth"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/brain\/awh175","volume":"127","author":"Polydefkis","year":"2004","journal-title":"Brain"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.pain.2013.04.044","volume":"154","author":"Mou","year":"2013","journal-title":"Pain"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/bjsports-2017-098043","volume":"52","author":"Zeng","year":"2018","journal-title":"Br J Sports Med"},{"key":"ref48","first-page":"5852","volume":"48","author":"Food","year":"1983","journal-title":"Fed Regist"},{"key":"ref49","first-page":"42324","volume":"68","author":"Food","year":"2003","journal-title":"Fed Regist"},{"key":"ref50","first-page":"63660","volume":"84","author":"Food","year":"2019","journal-title":"Fed Regist"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2147\/JPR.S116091","volume":"9","author":"Arnet","year":"2016","journal-title":"J Pain Relief"},{"key":"ref52","first-page":"487","volume":"12","author":"Kathe","year":"2017","journal-title":"Asian J Pharmaceut Sci"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.2147\/DDDT.S187177","volume":"12","author":"Zhao","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390","volume":"8","author":"Ita","year":"2016","journal-title":"Pharmaceutics"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ejps.2013.05.005","volume":"50","author":"Tuan-Mahmood","year":"2013","journal-title":"Eur J Pharm Sci"}],"container-title":["Journal of Pain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=61654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=61654","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T04:28:18Z","timestamp":1600748898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/characteristics-of-analgesic-patch-formulations-peer-reviewed-article-JPR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":55,"URL":"https:\/\/doi.org\/10.2147\/jpr.s270169","relation":{},"ISSN":["1178-7090"],"issn-type":[{"value":"1178-7090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}